UNIVERSITY OF WASHINGTON
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Preferred Treatment of Type 1.5 Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 64
- Registration Number
- NCT00194896
- Locations
- πΊπΈ
DVA Puget Sound Health Care System, Seattle, Washington, United States
Cefpodoxime vs Ciprofloxacin for Acute Cystitis
Not Applicable
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 300
- Registration Number
- NCT00194532
- Locations
- πΊπΈ
University of Miami Miller School of Medicine, Miami, Florida, United States
πΊπΈUniversity of Washington, Seattle, Washington, United States
Cerebral Perfusion Pressure (CPP) Management Information Feedback and Nursing
Not Applicable
Completed
- Conditions
- Traumatic Brain InjurySubarachnoid Hemorrhage
- Interventions
- Other: Bedside display of cerebral perfusion pressure information
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 260
- Registration Number
- NCT00194441
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
Phase 2
Terminated
- Conditions
- Estrogen Receptor-positive Breast CancerStage IIIA Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast Cancer
- Interventions
- Drug: exemestaneDrug: triptorelin pamoateDrug: capecitabineDrug: methotrexateDrug: vinorelbine tartrateDrug: paclitaxelProcedure: therapeutic conventional surgeryRadiation: radiation therapyOther: laboratory biomarker analysis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 28
- Registration Number
- NCT00194792
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
Phase 3
Completed
- Conditions
- HIV InfectionHerpes Simplex, GenitalSexually Transmitted Diseases
- Interventions
- Drug: Generic acyclovirDrug: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3408
- Registration Number
- NCT00194519
- Locations
- πΊπ¬
Mulago Hospital - IDI, Kampala, Uganda
π·πΌProjet San Francisco-Emory University, Kigali, Rwanda
π°πͺUniversity of Nairobi, Nairobi, Kenya
Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)
Phase 4
Suspended
- Conditions
- ProstatitisChronic Male Pelvic Pain Syndrome
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00194636
- Locations
- πΊπΈ
University of Washington - Urology Clinic, Seattle, Washington, United States
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-09-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT00194649
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
Childhood Chronic Illness: An Educational Program for Parents of Children With On-Going Health Care Needs
Not Applicable
Completed
- Conditions
- Chronic Illness
- Interventions
- Behavioral: 7 week Building on Family Strengths Program
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 129
- Registration Number
- NCT00194584
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
Phase 2
Completed
- Conditions
- Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IA Breast CancerStage IB Breast CancerHER2-positive Breast CancerStage IIIA Breast CancerStage II Breast Cancer
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: paclitaxelBiological: filgrastimDrug: capecitabineDrug: methotrexateDrug: vinorelbine tartrateProcedure: needle biopsyProcedure: therapeutic conventional surgeryOther: immunohistochemistry staining methodBiological: trastuzumabDrug: tamoxifen citrateDrug: letrozoleOther: laboratory biomarker analysis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT00194779
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Couples Miscarriage Healing Project:Randomized Trial
Phase 1
Completed
- Conditions
- MiscarriageGriefPregnancy Loss
- Interventions
- Behavioral: Nurse CaringBehavioral: Self CaringBehavioral: Combined Caring
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 682
- Registration Number
- NCT00194844
- Locations
- πΊπΈ
University of Washington School of Nursing, Seattle, Washington, United States
Β© Copyright 2025. All Rights Reserved by MedPath